- Access the segment here  HOUSTON, June  04, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (&#34;Moleculin&#34; or the &#34;Company&#34;), today announced that Walter Klemp, Chairman and Chief Executive Officer of

MBRX

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment

Moleculin's MIRACLE interim data could be inflection point in AML program

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>- Access the segment here  HOUSTON, June  04, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (&amp;#34;Moleculin&amp;#34; or the &amp;#34;Company&amp;#34;), today announced that Walter Klemp, Chairman and Chief Executive Officer of</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Moleculin Biotech announced the 45th subject enrollment in its MIRACLE MB-108 trial evaluating Annamycin with cytarabine for relapsed/refractory AML, with interim data unblinding expected mid-2026. The milestone could mark a pivotal inflection point as de-risking inputs from the MB-106 program and FDA discussions aim to support development. Financing remains a key backdrop, as milestones depend on securing additional capital.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>45th subject enrolled in MIRACLE MB-108 trial; interim data unblinding expected mid-2026.</li><li>CEO Klemp says milestone could be inflection point; final prep for interim data underway.</li><li>AnnAraC (Annamycin + cytarabine) targets R/R AML; development path de-risked by FDA input.</li><li>Financing needs: Moleculin may require significant additional funding to run trials.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Moleculin Biotech, Inc. (MBRX)</strong>: Primary company; milestone could influence stock trajectory amid mid-2026 data.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article describes a clinical-trial milestone and management commentary, a typical driver of speculative biotech stock moves like MBRX on binary data events.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Binary milestone: 45th enrollment; mid-2026 interim data could trigger re-rating.</li><li>Positive interim data could drive MBRX stock reaction.</li><li>Financing risk remains; milestones depend on timely funding.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>45th subject enrolled in MB-108 MIRACLE trial evaluating Annamycin + cytarabine.</li><li>Interim data unblinding targeted for mid-2026; trial milestones hinge on this.</li><li>MB-106 Phase 1B/2 study had FDA input; de-risked development pathway.</li><li>Annamycin is also known as naxtarubicin; lead program for AML.</li><li>Moleculin states significant additional financing is required to conduct trials.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>If interim data are favorable, MBRX could rally ahead of mid-2026; financing risk remains.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><i>- Access the segment </i><a href="https://www.globenewswire.com/Tracker?data=m3wvkghcJspr424sMTW5PyO_mO_W69Kzvf8P6gK7hkMRSxjgV8Zwd3iomNTJU5yoU3n-pcVZWzfJHwYOognGD67MrwE78eAHxmL5WI0UCHo=" rel="nofollow" target="_blank"><i>here</i></a><br></br></p>  <p align="justify"><b>HOUSTON, June  04, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.</b>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MBRX">MBRX</a>) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a <a href="https://www.globenewswire.com/Tracker?data=Vcql5BjsEzpigwdxjvW8ZDYrMcMk90phQbNiLmCsW3b4QWqyoEt4AylXFw5XAdt3rgQLUJMZeFnrFkxkM8Tex3hCgYfg2bIYmvj4CojOrH18_fLlcoFQIqszZBXzTj6qmoqeYy0eo1slFxG96mYPvQ==" rel="nofollow" target="_blank">Virtual Investor "What This Means" segment</a>.</p>  <p align="justify">As part of the segment, Mr. Klemp discussed the Company's recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.</p>  <p align="justify">The segment is now available for on-demand viewing <a href="https://www.globenewswire.com/Tracker?data=m3wvkghcJspr424sMTW5P7DSIkKN3l3IUI6lekSfHBz-3yZaJ1qQdhDORjGwj3kkVjAioom4_APyEbsc4wbEjyUWsr4aeM4gt-nBt7XGNw8=" rel="nofollow" target="_blank">here</a>.</p>  <p><b>About Moleculin Biotech, Inc.</b></p>  <p align="justify">Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.</p>  <p align="justify">The Company has begun the MIRACLE (<b>M</b>olecul<b>i</b>n <b>R</b>/R AML <b>A</b>nnAraC <b>Cl</b>inical <b>E</b>valuation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as "Ara-C") for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.</p>  <p align="justify">Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. </p>  <p align="justify">For more information about the Company, please visit <a href="https://www.globenewswire.com/Tracker?data=p574KX2SQIb2MDrmTMmUbLhqjajEZBD_wNU12Qe6USIcGaFXE-OuhqMhj0BZLY7n9iWh35ieZyDu86YO_9m1yML_qED64PFAYgyg28j7Jos=" rel="nofollow" target="_blank">www.moleculin.com</a> and connect on <a href="https://www.globenewswire.com/Tracker?data=caH2m4dSr1aIIqDA06KR0G_gbHk8941m5yUlp7ZAv8eV46dxDiDTb6d14lc7xBSX4IA1QWjWI5buOru7KV1tzg==" rel="nofollow" target="_blank">X</a>, <a href="https://www.globenewswire.com/Tracker?data=9QADdf797Q7NdxVNLERZl9BLXZNoC9PISZCAnsmg4QiZXIdncGEQh-x6xCi_X44INywgv7y11hjxQqDzudcRVC36uf1PCwzH6aLQegN2YgGLb2tKcjbT-azs0EPj12hE" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=KHYHkLWBAkQwkGt4ZoBO4VpVmiiTWPgo6J02qaaie7wPN78wTRJ-bYzG3W5ArE05BpWtoATllrwIWFA42hY5R0LdOTShq95aYWscEenAQO8=" rel="nofollow" target="_blank">Facebook</a>.</p>  <p align="justify"><b>Forward-Looking Statements</b><br></br>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the expected timing and results of the 45-subject interim data unblinding in the MIRACLE trial, the anticipated clinical milestones set forth above, and the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and other indications. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,' ‘estimates,' ‘anticipates,' ‘expects,' ‘plans,' ‘projects,' ‘intends,' ‘potential,' ‘may,' ‘could,' ‘might,' ‘will,' ‘should,' ‘approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>  <p><b>Investor Contact:</b><br></br>JTC Team, LLC<br></br>Jenene Thomas<br></br>(908) 824-0775<br></br><a href="https://www.globenewswire.com/Tracker?data=EOOpISuCMZy5N-GLcgpd8yNx06r6NkF3II7QKV34TWglK_WigK_3AA_gTkr7tcsKHA5Nw0wmYYh7WQtvT524FA==" rel="nofollow" target="_blank">MBRX@jtcir.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZjE2MzgyZTQtNTVhNS00OWUzLTk5MDktZDBlMTU0NDVlN2VhLTUwMDEzMzYwNy0yMDI2LTA2LTA0LWVu/tiny/Moleculin-Biotech-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/7fa09722-2ef8-49fc-bc24-6b150093f8ba"><img src="https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png" border="0" width="150" height="56" alt="Primary Logo"></img></a></p>

Moleculin Biotech announced the 45th subject enrollment in its MIRACLE MB-108 trial evaluating Annamycin with cytarabine for relapsed/refractory AML, with interim data unblinding expected mid-2026. The milestone could mark a pivotal inflection point as de-risking inputs from the MB-106 program and FDA discussions aim to support development. Financing remains a key backdrop, as milestones depend on securing additional capital.

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News